See the DrugPatentWatch profile for Mirena
Does Mirena (levonorgestrel IUD) increase breast cancer risk?
Mirena is a levonorgestrel-releasing intrauterine device (a progestin-only contraceptive). The key question for users is whether long-term local progestin exposure translates into a higher breast cancer risk compared with not using hormonal contraception.
Based on the information provided here, there are no specific study results, regulatory reviews, or quantified risk figures to cite for “Mirena breast cancer risk.” To answer accurately, I would need at least one of the following: the country/regulator you care about (FDA/EMA/UKMHRA, etc.), whether you mean absolute risk or relative risk, and which study type (cohort, case-control, meta-analysis) or guideline summary you want referenced.
How do researchers separate “Mirena risk” from general hormonal contraception risk?
People often search this because breast cancer risk signals in the literature are frequently tied to broader categories (combined estrogen-progestin pills vs. progestin-only methods vs. non-hormonal contraception). The mechanism can differ:
- Combined methods include estrogen exposure.
- Mirena releases levonorgestrel locally in the uterus, with lower systemic levels than many pills.
But without the provided evidence set, I can’t responsibly state whether Mirena specifically raises, lowers, or shows no measurable change in risk.
If you already have breast cancer (or a high-risk family history), is Mirena ever recommended?
This is a common practical concern. Clinical guidance typically depends on:
- Current vs past breast cancer
- Hormone-receptor status (ER/PR positive vs negative)
- Time since treatment
- Alternative contraception options
However, the exact recommendation for Mirena in these scenarios requires guideline or prescribing information you haven’t included here.
What do patients usually ask next: “How much higher is the risk, and for how long?”
When evidence exists, risk is usually discussed as:
- Relative risk (e.g., hazard/odds ratio)
- Absolute risk (extra cases per 10,000 women over a fixed time)
- Duration (risk during use vs after stopping)
If you share which resource or jurisdiction you’re using (or paste the specific study/guideline text), I can translate it into plain-language numbers and timeframe.
Are there patent/drug-coverage sources relevant to Mirena breast cancer risk?
DrugPatentWatch.com focuses on patents and market exclusivity for drugs and does not typically provide clinical risk assessments for breast cancer. It’s not a primary source for “Mirena breast cancer risk” claims.
What I need from you to give a precise, sourced answer
Reply with any one of these, and I’ll produce a specific risk-focused answer:
1) Your country (US/UK/EU/etc.) or the regulator/guideline you’re following
2) Whether you mean: “ever use,” “current use,” or “risk after stopping”
3) Whether you want comparisons vs copper IUD, vs progestin-only pills, or vs combined pills
4) Any study/guideline link or excerpt you want summarized
Sources
No sources were provided in the prompt to cite.